Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.
Molecular Aspects of Medicine
December 2023
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
npj Vaccines
October 2021
Nature Communications
May 2020
Filter by Category
Title | Disease Target | Product |
---|---|---|
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
Molecular Therapy - Oncolytics — March 2023 |
Disease TargetGlioblastoma Multiforme | ProductEGFRvIII-DBTE |
Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo
Frontiers in Immunology — February 2023 |
Disease TargetMelanoma | ProductAntibody-cytokine chimera TA99-HL2-KOA1 with DLnano-vaccine |
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019 |
Disease TargetHER2 |
Title | Disease Target | Product |
---|---|---|
Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation
Molecular Therapy - Nucleic Acids — December 2023 |
Disease TargetDelivery | ProductVacuum-assisted Intradermal EP |
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses
Vaccine — June 2019 |
Disease TargetDelivery | ProductCELLECTRA |
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
Vaccine — September 2011 |
Disease TargetDelivery | ProductCELLECTRA |
Title | Disease Target | Product |
---|---|---|
Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models
Human Vaccines & Immunotherapeutics — November 2023 |
Disease TargetCOVID-19 | ProductINO-4800 |
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022 |
Disease TargetCOVID-19 | ProductINO-4800 |
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020 |
Disease TargetCOVID-19 | ProductINO-4800 |
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.